Clinical Trials
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.
Soligenix Strengthens CTCL Advisory Board to Advance HyBryte Therapy Development
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the clinical advancement of HyBryte and related therapies, reflecting the company's strategic focus on navigating complex regulatory and commercialization challenges in the rare disease space.
American Heart Association Launches Initiative to Accelerate Aortic Stenosis Diagnosis and Clinical Trial Access
The American Heart Association has launched a new initiative to improve early diagnosis of aortic stenosis and increase participation in clinical trials, potentially transforming care for this serious heart condition that often goes undiagnosed until advanced stages.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
Cybin Secures $175 Million in Funding to Advance Mental Health Therapeutics
Cybin Inc. has closed a $175 million registered direct offering with top healthcare investors, providing critical capital to advance its Phase 3 clinical programs for novel mental health treatments addressing major depressive disorder and generalized anxiety disorder.
Cybin Chief Medical Officer to Present at Prestigious 2025 Milken Institute Health Summit
Cybin Inc.'s Chief Medical Officer will participate in the 2025 Milken Institute Future of Health Summit, highlighting the company's advanced clinical-stage mental health treatments and their potential to address significant unmet medical needs.
GeoVax Relocates Headquarters and Labs to Atlanta Area to Fuel Growth and Pipeline Advancement
GeoVax Labs is relocating its corporate headquarters and laboratory operations to new Atlanta-area facilities, positioning the clinical-stage biotechnology company for accelerated growth, late-stage development, and future commercialization of its cancer and infectious disease therapies.
Combining Healthy Lifestyle Habits with GLP-1 Medications Reduces Cardiovascular Risk in Type 2 Diabetes Patients
A study of over 63,000 veterans with Type 2 diabetes found that combining GLP-1 receptor agonist medications with at least six healthy lifestyle habits reduced cardiovascular event risk by 50% compared to standard care alone.
Low-Dose Aspirin Shows Cardiovascular Benefits for High-Risk Type 2 Diabetes Patients
A preliminary study suggests adults with Type 2 diabetes and moderate-to-high cardiovascular risk who take low-dose aspirin experience significantly lower rates of heart attack, stroke, and death compared to non-users, though bleeding risks require careful consideration.
Cybin Secures $175 Million in Registered Direct Offering to Advance Mental Health Treatments
Cybin Inc. has raised $175 million through a registered direct offering, providing crucial funding to advance its late-stage clinical trials for novel mental health treatments including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
Lifordi Immunotherapeutics Advances Glucocorticoid ADC LFD-200 into Phase 1 Rheumatoid Arthritis Trial Following Promising Nonclinical Data
Lifordi Immunotherapeutics has initiated Phase 1 clinical trials for LFD-200, a novel antibody-drug conjugate that delivers glucocorticoids directly to immune cells, potentially overcoming the systemic toxicity limitations that have restricted steroid use in autoimmune diseases for decades.
Oncotelic Therapeutics to Present Novel Breast Cancer Treatment Data at 2025 Symposium
Oncotelic Therapeutics will present clinical data for its investigational breast cancer treatment Sapu003 at the 2025 San Antonio Breast Cancer Symposium, potentially offering improved efficacy and reduced toxicity for patients with HR⁺/HER2⁻ metastatic breast cancer.
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Lantern Pharma Reports Complete Response in AI-Driven Cancer Drug Trial
Lantern Pharma's AI-developed drug LP-284 achieved a complete metabolic response in a heavily pre-treated lymphoma patient, demonstrating the potential of artificial intelligence to accelerate oncology drug development and address critical treatment gaps.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Soligenix's HyBryte Shows Promise as Potential First-Line Treatment for Cutaneous T-Cell Lymphoma
Soligenix Inc. is advancing HyBryte as a potential first-line therapy for early-stage cutaneous T-cell lymphoma following promising results from clinical trials that could reshape treatment standards in the rare disease space.
Pentixapharm Restructures Operations with 50% Workforce Reduction to Focus on Advanced Clinical Programs
Pentixapharm Holding AG is implementing significant organizational changes including a 50% workforce reduction and reduced early-stage research to concentrate resources on its most advanced clinical development programs, particularly the Phase 3-ready CXCR4 program for treatment-resistant hypertension diagnosis.
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.